First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
Status:
Terminated
Trial end date:
2011-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety, tolerability and the way the body handles
various single and multiple doses of ARC19499 in patients with hemophilia.